EGFR and glioma: Some of the documented mechanisms include the acquisition of secondary EGFR point mutations, co-activation and/or amplification of other receptor tyrosine kinases (RTKs), and up-regulation of drug efflux pumps, however, mechanisms of resistance that are unique to glioma are not clearly defined [12, 13].